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Most cancer patients die of metastatic or recurrent disease, hence the importance to identify target genes upregulated in these
lesions. Although a variety of gene signatures associated with metastasis or poor prognosis have been identified in various cancer
types, it remains a critical problem to identify key genes as candidate therapeutic targets in metastatic or recurrent cancer. The aim of
our study was to identify genes consistently upregulated in both lymph node micrometastases and recurrent tumours compared to
matched primary tumours in human cervical cancer. Taqman Low-Density Arrays were used to analyse matched tumour samples,
obtained after laser-capture microdissection of tumour cell islands for the expression of 96 genes known to be involved in tumour
progression. Immunohistochemistry was performed for a panel of up- and downregulated genes. In lymph node micrometastases,
most genes were downregulated or showed expressions equal to the levels found in primary tumours. In more than 50% of lymph
node micrometastases studied, eight genes (AKT, BCL2, CSFR1, EGFR1, FGF1, MMP3, MMP9 and TGF-b) were upregulated at least
two-fold. Some of these genes (AKT and MMP3) are key regulators of epithelial–mesenchymal transition in cancer. In recurrent
tumours, almost all genes were upregulated when compared to the expression profiles of the matched primary tumours, possibly
reflecting their aggressive biological behaviour. The two genes showing a consistent downregulated expression in almost all lymph
node metastases and recurrent tumours were BAX and APC. As treatment strategies are very limited for metastatic and recurrent
cervical cancer, the upregulated genes identified in this study are potential targets for new molecular treatment strategies in
metastatic or recurrent cervical cancer.
British Journal of Cancer (2007) 96, 321–328. doi:10.1038/sj.bjc.6603543 www.bjcancer.com
& 2007 Cancer Research UK
Keywords: molecular profiling; cervical cancer; lymph node; micrometastases; recurrent tumours
                                                         
Cervical cancer is one of the leading causes of death in women
worldwide, especially in developing countries owing to the lack of
adequate screening programmes. The causative agent of cervical
carcinogenesis is human papillomavirus (HPV), with insertion of
viral oncogenes into the host DNA (Walboomers et al, 1999). More
than 100 different HPV types have been identified and those
associated with cervical cancer are subdivided as high-risk types,
such as HPV16 and HPV18 (zur Hausen, 2000, 2002). However, the
molecular mechanisms controlling cervical cancer progression are
poorly understood.
Meta-analysis of DNA microarray data in cancer has revealed
that hundreds of genes are differentially expressed between cancer
tissues, including cervical cancer and their normal counterparts
(Shim et al, 1998; Rubin et al, 2004; Segal et al, 2004; Hudelist et al,
2005). It became evident that many of these genes are epipheno-
mena and that only a subset of genes is associated with tumour
progression and metastasis (Ramaswamy et al, 2003; Roepman
et al, 2005). In cervical cancer, gene expression profiling could be a
useful tool for molecular classification and prediction of treatment
response, but large studies are lacking (Wong et al, 2003). A 17-
gene signature has been associated with metastasis in a variety of
human solid tumours, including lung, breast, prostate, colorectal,
uterine and ovarian cancer (Ramaswamy et al, 2003). However,
none of these genes represented markers of metastasis, and the
signature reflected the gene expression profile of both neoplastic
and stromal cells. To identify key genes involved in a particular
cancer progression model it is essential to analyse matched tumour
samples of different stages. These studies could direct new
therapeutic strategies targeting specific candidate genes. Although
a variety of genes have been implicated in cervical cancer invasion,
migration and lymph node metastasis, most studies have used
only cervical cancer cell lines or primary tumours (Shim et al,
1998; Ruutu et al, 2002; Van Trappen et al, 2002; Vazquez-Ortiz
et al, 2005a). To our knowledge, no data are available on gene
expression profile differences between primary tumours and
matched metastatic or recurrent tumours in cervical cancer.
In this report, we attempt to identify genes up- or down-
regulated in lymph node micrometastases and recurrent tumours
when compared with the matched primary tumours. To explore
the gene expression profile of cervical cancer cells we used
Received 13 July 2006; revised 21 November 2006; accepted 22
November 2006
*Correspondence: Professor POA Van Trappen, Department of
Gynaecology/Oncology, Academic Hospital Maastricht (azM),
P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands;
E-mail: pvta@sgyn.azm.nl
British Journal of Cancer (2007) 96, 321–328
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
slaser-capture microdissection to extract tumour cell islands.
Taqman Low-Density Array, based on quantitative real-time
RT–PCR, was used to screen matched tumour samples for 96
selected genes involved in several molecular processes such as
angiogenesis, matrix degradation, cell cycle, oncogenic pathways,
DNA repair mechanisms, adhesion, invasion, migration, cell
proliferation and apoptosis. Immunohistochemistry was per-
formed for several up- and downregulated genes.
MATERIALS AND METHODS
Tissue specimens
Tumour specimens were obtained from cervical cancer patients
who underwent a radical hysterectomy and bilateral pelvic lymph
node (LN) dissection for early-stage cervical cancer International
Federation of Gynecology and Obstetrics (FIGO)-stage I–II at the
Gynecological Cancer Centre of St Bartholomew’s Hospital and the
Department of Obstetrics and Gynecology of the Clinical Centre
of Serbia between January 1999 and December 2002. From those
patients, surgical specimens were formalin fixed immediately after
removal and archival paraffin-embedded tissue was retrieved of
following tissues, primary tumours, paired lymph nodes with
micrometastasis or recurrent tumours where available. Patients
were staged according to the guidelines of the FIGO. All specimens
were reviewed by a pathologist (NS) of the Histopathology
Department at St Bartholomew’s Hospital and standard clinico-
pathological features (grade, histological subtype and lymph node
metastasis) were recorded. All primary tumour samples included
in the study were squamous cell carcinomas (SCC) with paired
lymph node micrometastases (between 200 and 2000mm according
to TNM classification) or recurrent tumours. The study was
approved by the East London and the City Local Research Ethics
Committee (T/02/046).
Microdissection, RNA extraction and RT–PCR
Before microdissection P.A.L.M slides (1mm pen slides, P.A.L.M.
Microlaser Technologies AG, Bernried, Germany) were first treated
with 1 RNAse Zap treatment for 2min and then washed three
times in DEPC water. After drying, the slides were sterilised in
UV light for 30min in a UV stratalinker (Stratagene, La Jolla, CA,
USA), membrane face up. Serial 7-mm paraffin sections were cut
with a fresh blade, mounted on prepared slides and incubated
at RT for 30min to achieve optimal tissue adhesion to the
membrane. All staining baths were washed with RNAse Zap before
use. Deparaffinisation was carried out by incubation in xylene
(2 2min), followed by washing and rehydration in ethanol (100%
ethanol 30s, 95% ethanol 30s, 70% ethanol 30s and H2O1 0 s
rinse). Sections were stained with haematoxylin for 1min and
washed twice for 1min in H2O. Dehydration followed, in ethanol
(70% ethanol 30s, 95% ethanol 2 30s, 100% ethanol 1min).
Slides were then ready after drying for processing by laser-assisted
microdissection (LAMD).
For haematoxilyin and eosin staining, sections were processed
as mentioned above. After dehydration in 70% ethanol for 30s,
slides were stained for 5s in eosin, then rinsed shortly in water.
The dehydration was completed as mentioned above.
Microdissection of the membrane-mounted sections (P.A.L.M.)
was performed with a high-resolution nitrogen UV laser (P.A.L.M.
MicroLaser System, Zeiss, Oberkochen, Germany). In brief, RNA
was extracted from laser microdissected tissue samples using
the Ambion paraffin block RNA isolation kit (Ambion, Austin, TX,
USA) according to the manufacturer’s instructions. After the
cutting event, the same laser was used to catapult the dissected
material into a microtube cap containing 100ml Proteinase K
digestion buffer (5ml proteinase K), incubated for 1h at 451C and
inactivated at 951C for 10min. A 600ml volume of RNA extraction
buffer was added and the sample was incubated for 5min at RT.
The sample was extracted using phenol:chloroform. The aqueous
layer was transferred to a fresh tube and mixed with 2ml linear
acrylamide. Isopropanol (1:1) precipitation was carried out
overnight. Following washing in 75% ethanol, the sample was
resuspended in 17mlH 2O. The RNA was DNase I (2Uml
 1) treated
for 15min at 371C.
Taqman Low-Density Arrays
Taqman Low-Density Arrays (Part No. 4342261, Applied Bio-
Systems, 850 Lincoln Centre Drive, Foster City, CA, USA) were
used for gene expression profiling based on real-time quantitative
RT–PCR to compare primary tumour and lymph node or
recurrence tissue. Briefly, 2mg DNase-treated RNA from each
sample was used for reverse transcription into 100ml cDNA. We
used Random Hexamers (Promega, Madison, WI, USA) and M-
MLV RT enzyme (Roche Diagnostics, Mannheim, Germany) to
synthesise cDNA. For each sample, 40ml of cDNA synthesised
above were then mixed with 210ml Taqman universal PCR master
mix (PE Applied Biosystems, New Jersey, NJ, USA) and 170ml
PCR water to form reaction mix. A 400ml portion of this reaction
mix was then put on microfluidic card into 192 mini wells
containing primers and probes of 96 genes in duplicate. These 96
genes, known to be involved in tumour progression, included DNA
damage repair genes, cell cycle control genes, common oncogenes,
tumour suppressor genes and metastasis-associated genes. Human
18S and GAPDH were used as endogenous controls. For each 384
well card, two cDNA samples (matched) were included at the same
time for real-time RT–PCR reaction and analysis. The real-time
RT–PCR reaction and laser scanning was performed on ABI
7900HT genotyper with SDS2.1 software. The expression level of
each gene is analysed on the mean of its duplicates. Only the genes
with reproducible amplification curves of both duplicates were
analysed and presented.
Immunohistochemistry
Immunohistochemical staining was performed for candidate
genes upregulated at mRNA level. Primary human monoclonal
antibodies to EGF-R (clone 1F4, Cell Signaling Technology, Inc. 3
Trask Lane, Danvers, MA, USA), AKT, FGF1, BCL2, CSF1R, MMP3
and MMP9 (R&D systems, Abingdon, UK), Her2/erbB2 (Cell
Signaling Technology, USA), phospho-Her2/erbB2 (Tyr1221/1222,
Cell Signaling Technology, USA) were used for staining. Briefly,
slides were blocked with horse serum (5min), incubated in a
humid chamber for 60min with primary antibody, and for 30min
each with biotinylated secondary antibody and avidin-biotinylated
horseradish peroxidase complex (ABC). Endogenous peroxidase
activity was blocked by 0.5% hydrogen peroxide (H2O2)i n
methanol for 15min. Washing was carried out using PBS buffer.
Colour development was obtained with 3,3-diaminobenzidine-
tetrahydrochloride for 10min. Sections were counterstained in
toluidine blue for 4min, washed for 4min in water, and dried in
ethanol. Sections were evaluated by quantitative analysis, the
number of immunohistochemical (IHC)-positive tumour cells were
calculated on the total number of tumour cells (percentage) in
three high-power fields per section. The median was calculated for
both primary tumours and metastases/recurrent tumours and
statistical differences were analysed using the Fisher’s Exact test.
RESULTS
We analysed 25 paired tumour samples for gene expression profile
differences: 11 primary cervical tumours with matched lymph
node micrometastases and 14 primary cervical tumours with
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smatched recurrent tumours. Laser-assisted microdissection was
used to extract tumour cell islands from those samples. The
appearance of tissue before and after microdissection is illustrated
in Figure 1. RNA was extracted and subsequent cDNA was
analysed using Taqman Low-Density Arrays. A summary of the
genes whose expression was altered consistently in replicate
experiments is presented in Figure 2. The figure shows genes
upregulated (red) or downregulated (green) (at least 2-fold) in the
lymph node micrometastases (n¼11) and recurrent tumours
(n¼14) respectively, when compared with the expression profiles
found in primary cervical tumours. Genes that did not vary in their
expression level are shown in white and genes with unsatisfactory
results (i.e. aberrant amplification curves or no expression) were
labelled black. The housekeeping gene GAPDH showed identical
expression levels in all matched samples analysed apart from one.
In lymph node micrometastases, most genes were down-
regulated or showed equal expression when compared with the
expression levels in primary cervical tumours. In more than half
(46/11) of these, there were eight genes consistently 42-fold
upregulated in lymph node micrometastases when compared with
primary tumours. These eight genes were AKT, BCL2, CSFR1,
EGFR1, FGF1, MMP3, MMP9 and transforming growth factor
(TGF)-b. Twenty-five genes were consistently o2-fold down-
regulated (Table 1).
In recurrent tumours, almost all genes were upregulated
(42-fold), possibly reflecting their aggressive biological beha-
viour. In total, 88 of 96 genes were upregulated (including the
eight genes commonly upregulated in lymph node micrometas-
tases) in more than 50% (47/14) of recurrent cases. The two genes
showing a consistent pattern of downregulated expression in both
lymph node micrometastases and recurrent tumours were BAX
and APC.
Immunohistochemical staining
Immunohistochemical (IHC) staining was performed for both
up- and downregulated gene(s) in all LN micrometastases (n¼11)
and compared to the staining results in the primary tumours.
Quantitative analysis was performed by calculating the number
of IHC-positive tumour cells on the total number of tumour cells
(percentage) in three high power fields per section. The median
was calculated for both primary tumours and lymph node
micrometastases and statistical differences were analysed using
the Fisher’s Exact test.
AKT was significantly upregulated in lymph node micro-
metasases when compared with the primary tumour (P¼0.0064;
Figure 3). Similarly, immunohistochemistry also confirmed
upregulation of CSF1R and EGFR in lymph node micrometastases
(data not shown). We could also confirm significant down-
regulation of ERBB2 (P¼0.0006; Figure 3). Immunohistochemical
differences for MMP3, MMP9, FGF1 and BCL2 were inconclusive
(data not shown). The reason therefore could either be the tissue
embedding technique or that there is still a post-transcriptional
modification of these genes.
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Figure 1 Slides of primary cervical cancers, lymph node micrometastases and recurrent tumours for haematoxylin and eosin (H&E) staining (first column;
4mm section) and haematoxylin (H) staining before (second column; 7mm section) and after microdissection (third column; 7mm section).
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COL1A1
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EGFR
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FGF2
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FOS
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GADD45A
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ICAM3
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KLK6
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LIG4
LMNB1
MAP2K4
MET
MAPK1
MDM2
MMP14
MMP2
MMP3
MMP7
MMP9
MMP11
MLH1
MMP1
MRE11A
MSH2
MUC1
MYC
NCOA3
NME1
NBS1
PIK3CA
PLAUR
RAD50
RAD51
RAD52
RB1
RAF1
RAD54L
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SPP1
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THBS1
THBS2
TGFB1
TP53
VCAM1
VEGFB
VIM
VIL2
VEGFC
VEGF
XRCC4
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Primary vs LN metastases Primary vs recurrence
Figure 2 Genes differentially expressed between LN micrometastases or recurrent tumours and matched primary cervical cancers. The figure shows
genes upregulated (red) or downregulated (green) (at least two-fold) in LNM (n¼11) and RT (n¼14) respectively, when compared with the expression
profiles found in primary tumours. Genes that did not vary in their expression level are shown in white, and genes with unsatisfactory results (i.e. aberrant
amplification curves or no expression) were labelled black.
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sDISCUSSION
In this study, we have investigated differential gene expression profiles
between LN micrometastases or recurrent tumours and matched
primary cervical cancers. We used a unique set of cervical cancer
samples from patients who underwent a radical hysterectomy and
pelvic lymph node dissection for presumed early-stage cervical cancer.
However, these patients demonstrated on histological examination
Table 1 Genes differentially expressed in lymph node micrometastases when compared with matched primary cervical cancers
Gene Gene name ID
Upregulated in LN metastases
AKT v-akt murine thymoma viral oncogenes homologue 1 Hs00178289_m1
BCL2 B-cell CLL/lymphoma 2 Hs00153350_m1
CSFR1 Colony-stimulating factor 1 receptor Hs00234617_m1
EGFR1 Epidermal growth factor receptor Hs00193306_m1
FGF1 Fibroblast growth factor 1 (acidic) Hs00265254_m1
MMP3 Matrix metalloproteinase 3 (stromelysin 1, progelatinase) Hs00233962_m1
MMP9 Matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase) Hs00234579_m1
TGFB Transforming growth factor, beta 1 Hs00171257_m1
Downregulated in LN metastases
APC Adenomatosis polyposis coli Hs00181051_m1
ARHA Ras homologue gene family, member A Hs00357608_m1
BRMS1 Breast cancer metastasissuppressor 1 (Interim) Hs00363036_m1
CCND1 Cyclin D1 (PRAD1: parathyroid adenomatosis 1) Hs00211039_m1
CCNE1 Cyclin E1 Hs00233356_m1
CD44 CD44 antigen (homing function and Indian blood group system) Hs00153310_m1
ERBB2 v-erb-b2 erythroblastic leukaemia viral oncogenes homologue 2 Hs00170433_m1
HLA-DPB1 Major histocompatibility complex, class II, DP beta 1 Hs00157955_m1
ITGAX Integrin, alpha X (antigen CD11C (p150), alpha polypeptide) Hs00174217_m1
JUN v-jun sarcoma virus 17 oncogene homologue (avian)) Hs00277190_m1
KLK6 Kallikrein 6 (neurosin, zyme) Hs00160519_m1
LMNB1 Lamin B1 Hs00194369_m1
MDM2 Mdm2, transformed 3T3 cell double minute 2, p53-binding protein Hs00242813_m1
MMP1 Matrix metalloproteinase 1 (interstitial collagenase) Hs00233958_m1
MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) Hs00159163_m1
MMP11 Matrix metalloproteinase 11 (stromelysin 3) Hs00171829_m1
MMP14 Matrix metalloproteinase 14 (membrane-inserted) Hs00237119_m1
MSH2 mutS homologue 2, colon cancer, nonpolyposis type 1 (Escherichia. coli) Hs00179887_m1
MUC1 Mucin 1, transmembrane Hs00410317_m1
MYC v-myc myelocytomatosis viral oncogenes homologue (avian) Hs00153408_m1
NME1 Nonmetastatic cells 1, protein (NM23A) expressed in Hs00264824_m1
SERPINB5 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member5 Hs00184728_m1
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homologue (avian) Hs00178494_m1
VCAM1 Vascular cell adhesion molecule 1 Hs00174239_m1
VIM Vimentin Hs00185584_m1
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Figure 3 Immunohistochemistry (IHC) for ERBB2 and AKT in matched primary cervical tumours and LN micrometastases. Quantitative analysis of IHC-
positive cells revealed that ERBB2 showed a significant stronger expression in the primary tumour (P¼0.0006), whereas AKT showed a significant stronger
expression in the LN metastases (P¼0.0064).
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identifiable on preoperative investigations (imaging) or during
surgery. Cervical cancers with LN metastases are normally treated
by primary chemo-radiotherapy, hence the unique set of matched
primary tumours and LN micrometastases obtained for this study.
In order to obtain expression profiles of tumour cell islands only
we used LAMD of paraffin-embedded tissue and microfluidic cards
based on real-time quantitative RT–PCR, a technique similar to that
described previously (Specht et al, 2001). This method was used,
as LN micrometastases can only be identified after histological
examination of paraffin-embedded tissue, and fresh frozen human
samples of LN micrometastases are difficult, if not impossible to
obtain. The microfluidic card contained 96 genes previously
described in tumour progression or identified as markers of
metastasis or clinical outcome (van ‘t Veer et al, 2002; Ramaswamy
et al, 2003; Rhodes and Chinnaiyan, 2004; Segal et al, 2004;
Roepman et al, 2005). Data obtained from microarrays of RNA
retrieved from paraffin-embedded tissue are not reliable hence our
application of microfluidic cards with selected genes. Although
microarrays could give a broader signature we aimed at identifying
a selective gene signature both in LN micrometastases and recurrent
tumours to identify markers as potential therapeutic targets. The 96
selected genes are involved in several molecular processes such
as angiogenesis, matrix degradation, cell cycle, oncogenic pathways,
DNA repair mechanisms, adhesion, invasion, migration, cell
proliferation and apoptosis. In LN metastases, most genes were
downregulated or showed equal expression with the levels found in
primary tumours, possibly reflecting their motility behaviour
requiring (temporarily) less molecular pathways compared with
primary tumours. In more than 50% of LN metastases, eight genes
were upregulated at least two-fold and 25 genes were downregulated
at least two-fold. In recurrent tumours, almost all genes were
upregulated at least two-fold, possibly reflecting their aggressive
biological behaviour. The two genes showing a consistent pattern of
downregulated expression in both LN metastases and recurrent
tumours were BAX and APC. The functional role of both genes has
been well described in cancer, with the BCL2 homologue gene
BAX playing a key role in tumour apoptosis as a proapoptotic gene
and APC acting as a tumour suppressor gene, which is frequently
inactivated in cervical cancer by hypermethylation (LeBlanc et al,
2002; Reesink-Peters et al, 2004; Soufla et al, 2005).
Here we describe eight genes (AKT, BCL2, CSFR1, EGFR1, FGF1,
MMP3, MMP9 and TGF-b) found to be commonly upregulated in
LN micrometastases in cervical cancer, as well as their functional
role previously described in cancer cell lines. These genes were
also upregulated in almost all recurrent tumours analysed making
them interesting targets for therapeutic strategies. AKT is a serine/
threonine kinase acting as a signal transduction protein and
downstream mediator of phosphatidylinositol-3-kinase (PI3K) that
plays a central role in tumour progression and influences
prognosis in several cancers (Lim et al, 2005; Tang et al, 2006).
The oncogenic pathway PI3K/AKT plays a central role in
epithelial–mesenchymal transition, a critical feature in cancer
invasion and metastasis by reducing intercellular adhesion and
increasing cancer cell motility (Larue and Bellacosa, 2005).
Upregulation of AKT in LN metastases in this study suggests its
potential role in epithelial–mesenchymal transition of cervical
cancer cells during metastasis. In the cervical cancer cell line C33A,
the PI3K/AKT pathway has a key role in cancer progression
towards a metastatic phenotype (Mora et al, 2006). BCL2 is an
antiapoptotic gene and increased expression is associated with
poor responses to systemic treatment of cancer (Andersen et al,
2005; Kausch et al, 2005). Colony stimulating factor-1 receptor
(CSFR1) is involved in tumour cell invasion and migration, and
high level expression is associated with poor prognosis in cancer
patients (Tsuzuki et al, 2005). In various cervical cancer cell lines
known to exhibit different degrees of aggressivity, the highest
levels of colony stimulating factor are found in the most aggressive
cell lines (Bretscher et al, 2000). The CSF1 produced by cancer cells
promotes the expression of EGF by macrophages (Goswami et al,
2005). In addition, EGF promotes the expression of CSF-1 by
cancer cells, thereby generating a positive feedback loop. Disrup-
tion of this loop by blockade of either EGF receptor or CSF-1
receptor signalling is sufficient to inhibit both macrophage and
tumour cell migration and invasion. Epidermal growth factor
receptor (EGFR) is highly expressed in many tumours, including
those of the cervix, and there is a clear relationship between HPV
E6/E7 oncoproteins and EGFR function (Hu et al, 1997). Blockade
of EGFR in cervical cancer cell lines induces increased expression
of genes that stimulate apoptosis and suppresses experimental
metastasis (Kim et al, 2004; Woodworth et al, 2005). Fibroblast
growth factor 1 (FGF1) is a growth factor for both tumour and
stromal (endothelial) cells and induces the expression of matrix
metalloproteinases (MMPs) and angiogenesis in cancer, hence
its involvement in tumour progression (Aonuma et al, 1998;
Kwabi-Addo et al, 2004; Udayakumar et al, 2004). The MMPs, a
family of proteolytic enzymes that degrade different components
of the extracellular matrix, play important roles in the different
stages of tumour progression. Matrix metalloproteinase 3 (stro-
melysin 1) plays an important role in breast cancer progression,
and it has shown to have increased levels, as well as activity, in
breast cancer brain metastasis in a rat model (Mendes et al, 2005).
Similar to AKT, MMP3 can also cause epithelial–mesenchymal
transition in cancer (Radisky et al, 2005). Matrix metalloproteinase
9 plays a central role in connective tissue degradation, tumour-
induced angiogenesis, cell proliferation/apoptosis and cell migration
in various tumour types including cervical cancer (van Kempen and
Coussens, 2002; Van Trappen et al, 2002; Zucker and Vacirca, 2004;
Vazquez-Ortiz et al, 2005b). Recently, one study has shown that
MMP9 forms a complex with the hyaluronan receptor CD44 on
the surface of breast cancer cells and activates downstream TGF-b,
facilitating tumour cell survival, invasion and metastasis (Yu and
Stamenkovic, 2004). Similar mechanism(s) could occur at the level
of tumour cell survival of LN micrometastases in cervical cancer.
Transforming growth factor (TGF)-b stimulates epithelial–
mesenchymal transition of SiHa cervical cancer cells, indicating a
positive role in the invasive transition of cervical cancer (Yi et al,
2002). Although TGF-b is both a tumour suppressor and tumour
promoter, TGF-b inhibitors are currently widely tested for the
treatment of cancer (Muraoka-Cook et al, 2004; Elliott and Blobe,
2005; Lahn et al, 2005). Various genes were downregulated in LN
micrometastases, such as major histocompatibility complex (MHC)
class II antigens and NME1. Underexpression of MHC molecules
involved in T-lymphocyte-mediated tumour cell recognition may be
one important escape mechanism used by metastatic cancer cells,
and these cells can be ignored by the immune system for a long time
despite the presence of immunocompetent cells (Pantel et al, 1991).
NME1, a metastasis-suppressor gene, shows reduced expression in
highly metastatic breast cancer cells and was downregulated in
cervical cancer LN metastases in this study (Rubio et al,2 0 0 6 ) .
Although several cancer gene signatures have shown prognostic
significance in a variety of cancers, it remains a critical problem to
identify key genes as candidate therapeutic targets. As cancer cells
require the expression of different genes along the different stages of
tumour progression, it is essential to obtain expression profile data
from the different steps of tumour progression. In this study, we have
identified a panel of tumour-associated genes upregulated in LN
micrometastases, as well as in recurrent tumours which could be
potential therapeutic targets in metastatic or recurrent cervical cancer.
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